Little is known regarding its biological function, but evidence from TANRIC16 shows differential expression of RP11-118E18.2 between carriers and non-carriers of mutations in clinically actionable genes including TP53, NAV3, MUC5B and MAP1A. Additionally, RP11-118E18.2 shows differential expression associated with ER status (P = 0.00026) and PR status (P = 0.001), PAM50 (P = 0.00046) and breast cancer therapy based on molecular signatures (P = 0.01) (Supplementary Fig. S3). This evidence concerns the gene MAP1A and breast cancer.